Author

J. Dilly

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. J. Aguirre· 2 shared A. A. Amparo· 1 shared A. C. Garcia· 1 shared A. L. Moriera· 1 shared A. R. Decker-Farrell· 1 shared A. S. Patel· 1 shared B. Bakir· 1 shared B. G. Neel· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. J. Aguirre

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

U. N. Wasko, J. Jiang, A. C. Garcia, Y. Wang, B. Lee, M. Orlen, K. Drizyte-Miller, M. Menard, J. Dilly, S. A. Sastra, C. F. Palermo, T. Dalton, M. C. Hasselluhn, A. R. Decker-Farrell, S. Chang, , R. H Vonderheide

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

bioRxiv · Dec 3, 2023 · PreprintCancer Biology

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

X. Tong, A. S. Patel, E. Kim, H. Li, Y. Chen, S. Li, S. Liu, J. Dilly, K. S. Kapner, Y. Xue, L. Hover, S. Mukhopadhyay, F. Sherman, K. Mynzdar, Y. Gao, , H. Ji

The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.

bioRxiv · Sep 7, 2023 · PreprintCancer Biology